{"id":30438,"date":"2025-05-21T12:20:56","date_gmt":"2025-05-21T02:20:56","guid":{"rendered":"https:\/\/template.reachmarkets.com.au\/investorportal\/?p=30438"},"modified":"2025-05-21T16:13:36","modified_gmt":"2025-05-21T06:13:36","slug":"shareholder-briefing-with-james-mcdonnell","status":"publish","type":"post","link":"https:\/\/template.reachmarkets.com.au\/investorportal\/shareholder-briefing-with-james-mcdonnell\/","title":{"rendered":"Shareholder Briefing with James McDonnell"},"content":{"rendered":"\n<section id=\"investor-briefing\" class=\"wp-block-gutentor-m3 section-gmd516642 gutentor-module gutentor-container-cover has-image-bg has-custom-bg\"><div class=\"grid-container\">\n<section id=\"gme673111\" class=\"wp-block-gutentor-m4 section-gme673111 gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gm4d1d59\" class=\"wp-block-gutentor-m4-col col-gm4d1d59 gutentor-single-column  grid-lg-12 grid-md-12 grid-12\"><div id=\"section-gm4d1d59\" class=\"section-gm4d1d59 gutentor-col-wrap\">\n<h2 class=\"wp-block-heading has-text-align-center has-white-color has-text-color\" style=\"font-size:33px\">Prescient Therapeutics: Shareholder Briefing with CEO James McDonnell<\/h2>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><\/p>\n<\/div><\/div>\n<\/div><\/div><\/section>\n\n\n\n<section id=\"gm100987c\" class=\"wp-block-gutentor-m4 section-gm100987c gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gmff66a2\" class=\"wp-block-gutentor-m4-col col-gmff66a2 gutentor-single-column  grid-lg-7 grid-md-6 grid-12\"><div id=\"section-gmff66a2\" class=\"section-gmff66a2 gutentor-col-wrap\">\n<figure class=\"wp-block-image size-full showvi\"><img loading=\"lazy\" decoding=\"async\" width=\"650\" height=\"360\" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/05\/PTX-Shareholder-Briefing.png\" alt=\"\" class=\"wp-image-30466\" srcset=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/05\/PTX-Shareholder-Briefing.png 650w, https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/05\/PTX-Shareholder-Briefing-300x166.png 300w\" sizes=\"auto, (max-width: 650px) 100vw, 650px\" \/><\/figure>\n\n\n\n<script src=\"https:\/\/ajax.googleapis.com\/ajax\/libs\/jquery\/3.5.1\/jquery.min.js\"><\/script>\n<script type=\"text\/javascript\"> \njQuery(document).ready(function ($) {\n    $('.showvi').click(function(e) {\n    e.preventDefault();\n  $('.showvi').html('<iframe loading=\"lazy\" src=\"https:\/\/player.vimeo.com\/video\/1086266569?title=0&#038;byline=0&#038;portrait=0\" width=\"100%\" height=\"410\" frameborder=\"0\" allow=\"autoplay; fullscreen\" allowfullscreen><\/iframe>');\n});\n});\n\n <\/script>\n<script type=\"text\/javascript\">jQuery(document).ready(function($){\n    $(\".showvi\").append(\"<img class='play-icon play-video' src='https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/07\/playvideo-3-1.svg' \/>\");\n});<\/script>\n<\/div><\/div>\n\n\n\n<div id=\"col-gmad60f4\" class=\"wp-block-gutentor-m4-col col-gmad60f4 gutentor-single-column  grid-lg-5 grid-md-6 grid-12 homepage-custom\"><div id=\"section-gmad60f4\" class=\"section-gmad60f4 gutentor-col-wrap\">\n<p class=\"has-white-color has-text-color\">CEO James McDonnell, held a shareholder briefing with Reach Markets.<\/p>\n\n\n\n<p class=\"has-white-color has-text-color\">In this session, James discussed:<\/p>\n\n\n\n<ul class=\"wp-block-list white\">\n<li>What to expect from our Phase 2a trial, with First Patient In and Dosed (FPID) anticipated in the coming weeks.<\/li>\n\n\n\n<li>How our promising Phase 1b results could help turn our Phase 2 trial into a registrational study.<\/li>\n\n\n\n<li>The significance of the Fast Track Designation granted by the FDA in April, and what it means for our potential accelerated path to commercialisation.<\/li>\n<\/ul>\n\n\n\n<p><\/p>\n\n\n\n<p class=\"has-white-color has-text-color\">Recorded on 21st May 2025 at 1pm (AEST)<\/p>\n\n\n\n<p><a href=\"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing\/\">Join the next Prescient Therapeutics webcast<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/template.reachmarkets.com.au\/investorportal\/register\/\">Register to stay up to date with Prescient Therapeutics<\/a><\/p>\n<\/div><\/div>\n<\/div><\/div><\/section>\n\n\n\n<section id=\"bio\" class=\"wp-block-gutentor-m3 alignwide section-gma827d63 gutentor-module gutentor-container-cover custom-fullwidth\"><div class=\"grid-container\">\n<h4 class=\"wp-block-heading speak has-text-color\" style=\"color:#ffcc00\">Featured Speaker<\/h4>\n\n\n\n<h3 class=\"wp-block-heading has-text-align-center speaker-heading has-white-color has-text-color\"><\/h3>\n\n\n\n<section id=\"gm6dd8ca2\" class=\"wp-block-gutentor-m4 section-gm6dd8ca2 gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gme4f44c\" class=\"wp-block-gutentor-m4-col col-gme4f44c gutentor-single-column  grid-lg-3 grid-md-12 grid-12\"><div id=\"section-gme4f44c\" class=\"section-gme4f44c gutentor-col-wrap\"><\/div><\/div>\n\n\n\n<div id=\"col-gm5f908e\" class=\"wp-block-gutentor-m4-col col-gm5f908e gutentor-single-column  grid-lg-6 grid-md-12 grid-12\"><div id=\"section-gm5f908e\" class=\"section-gm5f908e gutentor-col-wrap\">\n<figure class=\"wp-block-image size-full speaker-img\"><img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"300\" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/03\/James_McDonnell_PTX.png\" alt=\"\" class=\"wp-image-30282\" srcset=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/03\/James_McDonnell_PTX.png 300w, https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/03\/James_McDonnell_PTX-150x150.png 150w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/figure>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"wp-block-heading has-text-align-center speaker-heading has-white-color has-text-color\">James McDonnell<\/h3>\n\n\n\n<h4 class=\"wp-block-heading has-text-align-center speaker-title has-white-color has-text-color\">CEO<\/h4>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-text-align-center speaker-bio has-white-color has-text-color\">James McDonnell is a seasoned leader in the biopharmaceutical industry, bringing over 25 years of global experience in pharmaceuticals, with a particular focus on blood disorders and hematological malignancies such as Myeloma, Myelodysplasia, and CML. <\/p>\n\n\n\n<p class=\"has-text-align-center speaker-bio has-white-color has-text-color\">Throughout his career, James has held senior leadership roles at renowned pharmaceutical companies, including Pharmion and CSL Vifor. At Pharmion, he spearheaded the growth of its oncology and hematology portfolio as Head of Global Marketing, contributing to the company&#8217;s acquistion by Celgene Corporation for US$2.9 billion. Most recently, James served as Global Commercial Lead for Patient Blood Management at CSL Vifor, where he drove key enterprise-wide strategic initiatives.<\/p>\n\n\n\n<p class=\"has-text-align-center speaker-bio has-white-color has-text-color\">James is a registered pharmacist and a member of the Royal Pharmaceutical Society. He holds a Graduate Diploma in Marketing from Monash University and is a graduate of the Australian Institute of Company Directors.<\/p>\n<\/div><\/div>\n\n\n\n<div id=\"col-gm784022\" class=\"wp-block-gutentor-m4-col col-gm784022 gutentor-single-column  grid-lg-3 grid-md-12 grid-12\"><div id=\"section-gm784022\" class=\"section-gm784022 gutentor-col-wrap\">\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"wp-block-heading has-text-align-center speaker-heading has-white-color has-text-color\"><\/h3>\n<\/div><\/div>\n<\/div><\/div><\/section>\n<\/div><\/section>\n<\/div><\/section>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":38,"featured_media":30466,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[29],"class_list":["post-30438","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-prescient-therapeutics"],"gutentor_comment":0,"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Shareholder Briefing with James McDonnell - PTX Therapeutics<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shareholder Briefing with James McDonnell - PTX Therapeutics\" \/>\n<meta property=\"og:url\" content=\"https:\/\/template.reachmarkets.com.au\/investorportal\/shareholder-briefing-with-james-mcdonnell\/\" \/>\n<meta property=\"og:site_name\" content=\"PTX Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-21T02:20:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-21T06:13:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/05\/PTX-Shareholder-Briefing.png\" \/>\n\t<meta property=\"og:image:width\" content=\"650\" \/>\n\t<meta property=\"og:image:height\" content=\"360\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Adrian Montesano\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Adrian Montesano\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/shareholder-briefing-with-james-mcdonnell\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/shareholder-briefing-with-james-mcdonnell\/\"},\"author\":{\"name\":\"Adrian Montesano\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/77eeea3f70b4075df3b2207ba88cc5b6\"},\"headline\":\"Shareholder Briefing with James McDonnell\",\"datePublished\":\"2025-05-21T02:20:56+00:00\",\"dateModified\":\"2025-05-21T06:13:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/shareholder-briefing-with-james-mcdonnell\/\"},\"wordCount\":252,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/shareholder-briefing-with-james-mcdonnell\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/05\/PTX-Shareholder-Briefing.png\",\"keywords\":[\"Prescient Therapeutics\"],\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\/shareholder-briefing-with-james-mcdonnell\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/shareholder-briefing-with-james-mcdonnell\/\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/shareholder-briefing-with-james-mcdonnell\/\",\"name\":\"Shareholder Briefing with James McDonnell - PTX Therapeutics\",\"isPartOf\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/shareholder-briefing-with-james-mcdonnell\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/shareholder-briefing-with-james-mcdonnell\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/05\/PTX-Shareholder-Briefing.png\",\"datePublished\":\"2025-05-21T02:20:56+00:00\",\"dateModified\":\"2025-05-21T06:13:36+00:00\",\"author\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/77eeea3f70b4075df3b2207ba88cc5b6\"},\"breadcrumb\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/shareholder-briefing-with-james-mcdonnell\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\/shareholder-briefing-with-james-mcdonnell\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/shareholder-briefing-with-james-mcdonnell\/#primaryimage\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/05\/PTX-Shareholder-Briefing.png\",\"contentUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/05\/PTX-Shareholder-Briefing.png\",\"width\":650,\"height\":360},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/shareholder-briefing-with-james-mcdonnell\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shareholder Briefing with James McDonnell\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#website\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/\",\"name\":\"PTX Therapeutics\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/77eeea3f70b4075df3b2207ba88cc5b6\",\"name\":\"Adrian Montesano\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/d23955e73043fde98cb92bd29b69f088f6103da014084b9f3e2fffa65e5558ea?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d23955e73043fde98cb92bd29b69f088f6103da014084b9f3e2fffa65e5558ea?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d23955e73043fde98cb92bd29b69f088f6103da014084b9f3e2fffa65e5558ea?s=96&d=mm&r=g\",\"caption\":\"Adrian Montesano\"},\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/author\/adrian-montesano\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Shareholder Briefing with James McDonnell - PTX Therapeutics","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Shareholder Briefing with James McDonnell - PTX Therapeutics","og_url":"https:\/\/template.reachmarkets.com.au\/investorportal\/shareholder-briefing-with-james-mcdonnell\/","og_site_name":"PTX Therapeutics","article_published_time":"2025-05-21T02:20:56+00:00","article_modified_time":"2025-05-21T06:13:36+00:00","og_image":[{"width":650,"height":360,"url":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/05\/PTX-Shareholder-Briefing.png","type":"image\/png"}],"author":"Adrian Montesano","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Adrian Montesano","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/shareholder-briefing-with-james-mcdonnell\/#article","isPartOf":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/shareholder-briefing-with-james-mcdonnell\/"},"author":{"name":"Adrian Montesano","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/77eeea3f70b4075df3b2207ba88cc5b6"},"headline":"Shareholder Briefing with James McDonnell","datePublished":"2025-05-21T02:20:56+00:00","dateModified":"2025-05-21T06:13:36+00:00","mainEntityOfPage":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/shareholder-briefing-with-james-mcdonnell\/"},"wordCount":252,"commentCount":0,"image":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/shareholder-briefing-with-james-mcdonnell\/#primaryimage"},"thumbnailUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/05\/PTX-Shareholder-Briefing.png","keywords":["Prescient Therapeutics"],"articleSection":["News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/template.reachmarkets.com.au\/investorportal\/shareholder-briefing-with-james-mcdonnell\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/shareholder-briefing-with-james-mcdonnell\/","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/shareholder-briefing-with-james-mcdonnell\/","name":"Shareholder Briefing with James McDonnell - PTX Therapeutics","isPartOf":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#website"},"primaryImageOfPage":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/shareholder-briefing-with-james-mcdonnell\/#primaryimage"},"image":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/shareholder-briefing-with-james-mcdonnell\/#primaryimage"},"thumbnailUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/05\/PTX-Shareholder-Briefing.png","datePublished":"2025-05-21T02:20:56+00:00","dateModified":"2025-05-21T06:13:36+00:00","author":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/77eeea3f70b4075df3b2207ba88cc5b6"},"breadcrumb":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/shareholder-briefing-with-james-mcdonnell\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/template.reachmarkets.com.au\/investorportal\/shareholder-briefing-with-james-mcdonnell\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/shareholder-briefing-with-james-mcdonnell\/#primaryimage","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/05\/PTX-Shareholder-Briefing.png","contentUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/05\/PTX-Shareholder-Briefing.png","width":650,"height":360},{"@type":"BreadcrumbList","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/shareholder-briefing-with-james-mcdonnell\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/template.reachmarkets.com.au\/investorportal\/"},{"@type":"ListItem","position":2,"name":"Shareholder Briefing with James McDonnell"}]},{"@type":"WebSite","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#website","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/","name":"PTX Therapeutics","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/template.reachmarkets.com.au\/investorportal\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/77eeea3f70b4075df3b2207ba88cc5b6","name":"Adrian Montesano","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/d23955e73043fde98cb92bd29b69f088f6103da014084b9f3e2fffa65e5558ea?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/d23955e73043fde98cb92bd29b69f088f6103da014084b9f3e2fffa65e5558ea?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d23955e73043fde98cb92bd29b69f088f6103da014084b9f3e2fffa65e5558ea?s=96&d=mm&r=g","caption":"Adrian Montesano"},"url":"https:\/\/template.reachmarkets.com.au\/investorportal\/author\/adrian-montesano\/"}]}},"_links":{"self":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/30438","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/comments?post=30438"}],"version-history":[{"count":11,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/30438\/revisions"}],"predecessor-version":[{"id":30530,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/30438\/revisions\/30530"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/media\/30466"}],"wp:attachment":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/media?parent=30438"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/categories?post=30438"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/tags?post=30438"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}